Lazard Asset Management
ACAD icon

Lazard Asset Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Lazard Asset Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.26M Buy
247,569
+1,272
+0.5% +$28K 0.01% 551
2026
Q1 		$5.48M Buy
246,297
+20,075
+9% +$480K 0.01% 539
2025
Q4 		$6.04M Buy
226,222
+53,401
+31% +$1.28M 0.01% 511
2025
Q3 		$3.69M Buy
172,821
+137,250
+386% +$3.25M 0.01% 664
2025
Q2 		$766K Sell
35,571
-151,930
-81% -$2.82M ﹤0.01% 1378
2025
Q1 		$3.11M Buy
187,501
+36,573
+24% +$664K ﹤0.01% 828
2024
Q4 		$2.77M Buy
150,928
+53,885
+56% +$870K ﹤0.01% 779
2024
Q3 		$1.49M Buy
97,043
+63,211
+187% +$1.05M ﹤0.01% 950
2024
Q2 		$549K Buy
33,832
+7,619
+29% +$123K ﹤0.01% 1165
2024
Q1 		$483K Buy
26,213
+17,719
+209% +$439K ﹤0.01% 1064
2023
Q4 		$265K Buy
8,494
+2,133
+34% +$50.9K ﹤0.01% 1300
2023
Q3 		$132K Buy
6,361
+2,236
+54% +$60.7K ﹤0.01% 1527
2023
Q2 		$98K Buy
4,125
+1,088
+36% +$24.2K ﹤0.01% 1585
2023
Q1 		$57K Buy
+3,037
New +$57.8K ﹤0.01% 1751
2022
Q4 		– Sell
-3,689
Closed -$60K – 2356
2022
Q3 		$60K Buy
+3,689
New +$59.7K ﹤0.01% 1710
2022
Q1 		– Sell
-3,115
Closed -$72K – 2304
2021
Q4 		$72K Buy
3,115
+506
+19% +$10.2K ﹤0.01% 1570
2021
Q3 		$43K Buy
+2,609
New +$50.3K ﹤0.01% 1743
2021
Q1 		– Sell
-1,356
Closed -$72K – 1834
2020
Q4 		$72K Hold
1,356
– – ﹤0.01% 1277
2020
Q3 		$55K Buy
+1,356
New +$58.6K ﹤0.01% 1157
2020
Q2 		– Sell
-4,060
Closed -$171K – 1601
2020
Q1 		$171K Sell
4,060
-57,786
-93% -$2.38M ﹤0.01% 920
2019
Q4 		$2.65M Buy
61,846
+61,031
+7,488% +$2.66M ﹤0.01% 632
2019
Q3 		$29K Buy
+815
New +$24.7K ﹤0.01% 1027

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Lazard Asset Management's ACAD Position: Q2 2026 in Review

Lazard Asset Management increased its Acadia Pharmaceuticals (ACAD) stake by 0.52% in Q2 2026, buying an estimated $28K and bringing the position to 247,569 shares worth $6.26M. The position accounts for 0.01% of the portfolio, ranked #551.

Lazard Asset Management first reported a position in ACAD in Q3 2019 and has held it in 22 quarters since. 353 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Lazard Asset Management held 247,569 shares of Acadia Pharmaceuticals worth $6.26M as of Q2 2026.
  • Lazard Asset Management bought 1,272 Acadia Pharmaceuticals shares in Q2 2026, an estimated $28K.
  • Acadia Pharmaceuticals made up 0.01% of Lazard Asset Management's portfolio in Q2 2026, its #551 holding.
  • Lazard Asset Management first reported a position in Acadia Pharmaceuticals in Q3 2019 and has held it in 22 quarters since.
  • 353 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Lazard Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.